TGTX
TG THERAPEUTICS, INC.
$40.16
-0.99%
$6.1B
No data for this timeframe.
Vol
Market Cap$6.1B
Cap SizeMid Cap
Analyst ConsensusStrong Buy (80%)
Inst. Holders7 funds
Inst. Value$631.7M
Inst. Activity2 buys / 1 sells
SEC Reports5
Press Releases6
Recent Activity
Jun 3, 2026
SEC
TG Therapeutics announced positive Phase 1 data for a subcutaneous formulation of BRIUMVI (ublituximab-xiiy), showing fa
8-K — Impact 7/10
May 27, 2026
SEC
TG Therapeutics announced positive topline results from the Phase 3 ENHANCE trial, which met its primary endpoint by dem
8-K — Impact 7/10
May 6, 2026
SEC
TG Therapeutics reported Q1 2026 revenue of $204.9M, well above the $201.2M consensus, and raised full-year 2026 BRIUMVI
8-K — Impact 7/10
Inst.
BANK OF AMERICA CORP — ADD
851,107 shares ($25.4M)
Inst.
WELLS FARGO & COMPANY/MN — ADD
395,680 shares ($11.8M)
Jun 3, 2026
Press
TG Therapeutics announced positive Phase 1 data for a subcutaneous formulation of BRIUMVI, showing favorable pharmacokin
Impact 7/10
Jun 3, 2026
fda
TG Therapeutics Announces Positive Results from Phase 1 Trial Evaluating Subcutaneous BRIUMVI® (ublituximab-xiiy)
<p><em>Pharmacokinetic and pharmacodynamic data support quarterly subcutaneous BRIUMVI dosing regime
Jun 1, 2026
Press
TG Therapeutics published a post-hoc pooled analysis of Phase 3 ULTIMATE I/II data in Frontiers in Immunology, showing B
Impact 5/10
Price Targets
$48.00
+19.5% upside
Buy
Current $40.16
Low $17.00
Median $50.00
High $70.00
7 analysts
$17.00
$70.00
Analyst Ratings
3Strong Buy
9Buy
2Hold
1Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 27, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| May 6, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Feb 2, 2026 | JP Morgan | MAINTAIN | Overweight → Overweight |
| Jan 15, 2026 | Goldman Sachs | MAINTAIN | Neutral → Neutral |
| Nov 3, 2025 | JP Morgan | MAINTAIN | Overweight → Overweight |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current FY | $1.54 ▲ +21.4% | $1.30 — $1.67 | -45% YoY | 4 |
| Next Q | $0.43 ▲ +40.3% | $0.39 — $0.46 | 167% YoY | 5 |
| Next FY | $2.87 ▲ +19.3% | $2.32 — $3.58 | 87% YoY | 5 |
| Current Q | $0.43 ▲ +33.9% | $0.31 — $0.59 | 151% YoY | 5 |
Latest Reports
BULLISH
8-K
7/10
TG Therapeutics announced positive Phase 1 data for a subcutaneous formulation of BRIUMVI (ublituximab-xiiy), showing fa
Jun 3, 2026
BULLISH
Press
7/10
TG Therapeutics announced positive Phase 1 data for a subcutaneous formulation of BRIUMVI, showing favorable pharmacokin
Jun 3, 2026
BULLISH
8-K
7/10
TG Therapeutics announced positive topline results from the Phase 3 ENHANCE trial, which met its primary endpoint by dem
May 27, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $472.2M | — |
| MORGAN STANLEY | $44.8M | TRIM |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $39.1M | NEW |
| TWO SIGMA INVESTMENTS, LP | $31.6M | ADD |
| BANK OF AMERICA CORP | $25.4M | ADD |
7 institutional holders with $631.7M total value (21,189,959 shares) as of 2025-Q4. Top holders: VANGUARD, MORGAN, CHARLES. Net buying activity: 2 institutions added/increased vs 1 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 15,841,002 | $472.2M | 74.8% | — |
| 2 | MORGAN STANLEY | 1,503,037 | $44.8M | 7.1% | TRIM -31.6% |
| 3 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1,311,689 | $39.1M | 6.2% | NEW |
| 4 | TWO SIGMA INVESTMENTS, LP | 1,060,448 | $31.6M | 5.0% | ADD +45.0% |
| 5 | BANK OF AMERICA CORP /DE/ | 851,107 | $25.4M | 4.0% | ADD +35.8% |
| 6 | WELLS FARGO & COMPANY/MN | 395,680 | $11.8M | 1.9% | ADD +45.1% |
| 7 | FMR LLC | 226,996 | $6.8M | 1.1% | TRIM -68.1% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| BANK OF AMERICA CORP /DE/ | ADD | 626,653 | 851,107 | +35.8% | $25.4M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 272,667 | 395,680 | +45.1% | $11.8M | 2025-Q4 |
| FMR LLC | TRIM | 711,343 | 226,996 | -68.1% | $6.8M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | ADD | 613,707 | 889,870 | +45.0% | $32.1M | 2025-Q3 |
| FMR LLC | TRIM | 1,551,973 | 711,343 | -54.2% | $25.7M | 2025-Q3 |
| NORGES BANK | EXIT | 89,820 | 0 | -100.0% | $0.00 | 2025-Q3 |
| MORGAN STANLEY | TRIM | 2,050,548 | 1,402,613 | -31.6% | $50.5M | 2025-Q2 |
| NORGES BANK | NEW | — | 89,820 | — | $3.2M | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 168,594 | 0 | -100.0% | $0.00 | 2025-Q2 |
| FMR LLC | ADD | 1,031,419 | 1,743,354 | +69.0% | $68.7M | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | ADD | 606,208 | 793,639 | +30.9% | $31.3M | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 168,594 | — | $6.6M | 2025-Q1 |
| NORGES BANK | EXIT | 401,495 | 0 | -100.0% | $0.00 | 2025-Q1 |
| CITADEL ADVISORS LLC | ADD | 719,634 | 1,384,060 | +92.3% | $41.7M | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 178,721 | 331,403 | +85.4% | $10.0M | 2024-Q4 |
| MORGAN STANLEY | ADD | 1,488,742 | 2,164,468 | +45.4% | $50.6M | 2024-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 1,184,609 | — | $27.7M | 2024-Q3 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
5 SEC filing reports analyzed. Sentiment: 4 bullish, 0 bearish, 0 mixed, 1 neutral. Avg impact: 6.2/10.
BULLISH
8-K
7/10
TG Therapeutics announced positive Phase 1 data for a subcutaneous formulation of BRIUMVI (ublituxim
Jun 3, 2026
BULLISH
8-K
7/10
TG Therapeutics announced positive topline results from the Phase 3 ENHANCE trial, which met its pri
May 27, 2026
BULLISH
8-K
7/10
TG Therapeutics reported Q1 2026 revenue of $204.9M, well above the $201.2M consensus, and raised fu
May 6, 2026
NEUTRAL
PRESS-RELEASE
2/10
TG Therapeutics announced a Q1 2026 earnings call for May 6, 2026, but did not release financial res
Apr 30, 2026
BULLISH
8-K
8/10
TG Therapeutics reported strong 2025 financial results with full-year revenue of $616.3 million, dri
Feb 26, 2026
BULLISH
7/10
TG Therapeutics announced positive Phase 1 data for a subcutaneous formulation of BRIUMVI, showing f
Jun 3, 2026
BULLISH
5/10
TG Therapeutics published a post-hoc pooled analysis of Phase 3 ULTIMATE I/II data in Frontiers in I
Jun 1, 2026
NEUTRAL
4/10
TG Therapeutics announced new real-world and dosing data for BRIUMVI® (ublituximab-xiiy) in relapsin
Apr 22, 2026
NEUTRAL
4/10
TG Therapeutics announced results from a Phase 3 trial evaluating two subcutaneous BRIUMVI dosing re
Apr 15, 2026
BULLISH
7/10
TG Therapeutics announced a new $750 million senior secured credit facility with Blue Owl Capital, u
Mar 19, 2026
BULLISH
7/10
TG Therapeutics released new post hoc pooled analysis data from its Phase 3 ULTIMATE I and II trials
Mar 9, 2026
Current analyst consensus: Strong Buy (80% buy). Based on 15 analysts: 3 strong buy, 9 buy, 2 hold, 1 sell, 0 strong sell.
Analyst Price Targets
$48.00 mean target
+19.5% upside
Buy (1.67)
$17.00 Low
$70.00 High
| Metric | Value |
|---|---|
| Current Price | $40.16 |
| Target Low | $17.00 |
| Target Mean | $48.00 |
| Target Median | $50.00 |
| Target High | $70.00 |
| # Analysts | 7 |
| Recommendation | Buy (1.67) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current FY 2026-12-31 |
$1.54 | $1.30 | $1.67 | -44.6% | +21.4% | 2↑ 0↓ | $0.9B | 52.7% | 4 |
| Next Q 2026-09-30 |
$0.43 | $0.39 | $0.46 | 167.1% | +40.3% | 2↑ 2↓ | $0.2B | 50.8% | 5 |
| Next FY 2027-12-31 |
$2.87 | $2.32 | $3.58 | 87.1% | +19.3% | 0↑ 2↓ | $1.2B | 31.7% | 5 |
| Current Q 2026-06-30 |
$0.43 | $0.31 | $0.59 | 151.2% | +33.9% | 0↑ 1↓ | $0.2B | 61.6% | 5 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $0.427 | |
| 7d ago | $0.456 | -0.029 |
| 30d ago | $0.319 | +0.108 |
| 60d ago | $0.341 | +0.086 |
| 90d ago | $0.343 | +0.084 |
9 analyst firms have rated this stock: 1 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 27, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 6, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Feb 2, 2026 | JP Morgan | MAINTAIN | Overweight | Overweight |
| Jan 15, 2026 | Goldman Sachs | MAINTAIN | Neutral | Neutral |
| Nov 3, 2025 | JP Morgan | MAINTAIN | Overweight | Overweight |
| Sep 17, 2025 | B. Riley Securities | MAINTAIN | Buy | Buy |
| Mar 4, 2025 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Jan 15, 2025 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Nov 25, 2024 | JP Morgan | MAINTAIN | Overweight | Overweight |
| Nov 5, 2024 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Nov 5, 2024 | Goldman Sachs | MAINTAIN | Neutral | Neutral |
| Oct 29, 2024 | TD Cowen | INITIATE | — | Buy |
| Sep 18, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Aug 7, 2024 | B. Riley Securities | MAINTAIN | Buy | Buy |
| Aug 7, 2024 | Goldman Sachs | MAINTAIN | Neutral | Neutral |
| Aug 6, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 2, 2024 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| May 2, 2024 | Ladenburg Thalmann | MAINTAIN | Buy | Buy |
| Apr 18, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Apr 18, 2024 | JP Morgan | REITERATE | Overweight | Overweight |
| Apr 18, 2024 | Ladenburg Thalmann | REITERATE | Buy | Buy |
| Mar 1, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Feb 29, 2024 | Goldman Sachs | MAINTAIN | Neutral | Neutral |
| Feb 28, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Feb 5, 2024 | B. Riley Securities | MAINTAIN | Buy | Buy |
| Jan 11, 2024 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Nov 1, 2023 | JP Morgan | MAINTAIN | Overweight | Overweight |
| Nov 1, 2023 | Jefferies | MAINTAIN | Buy | Buy |
| Oct 20, 2023 | B. Riley Securities | MAINTAIN | Buy | Buy |
| Sep 18, 2023 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Aug 7, 2023 | JP Morgan | MAINTAIN | Overweight | Overweight |
| Aug 3, 2023 | Goldman Sachs | MAINTAIN | Neutral | Neutral |
| Aug 2, 2023 | B. Riley Securities | MAINTAIN | Buy | Buy |
| Aug 2, 2023 | Goldman Sachs | UPGRADE | Sell | Neutral |
| Aug 1, 2023 | B. Riley Securities | REITERATE | Buy | Buy |
| Aug 1, 2023 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Jul 25, 2023 | Goldman Sachs | MAINTAIN | Sell | Sell |
| Jul 24, 2023 | Goldman Sachs | MAINTAIN | Sell | Sell |
| Jul 13, 2023 | B. Riley Securities | REITERATE | Buy | Buy |
| Jun 1, 2023 | HC Wainwright & Co. | REITERATE | — | Buy |
| May 31, 2023 | HC Wainwright & Co. | REITERATE | — | Buy |
| May 2, 2023 | Ladenburg Thalmann | MAINTAIN | — | Buy |
| May 1, 2023 | HC Wainwright & Co. | REITERATE | — | Buy |
| Apr 17, 2023 | Cantor Fitzgerald | REITERATE | — | Overweight |
| Apr 14, 2023 | HC Wainwright & Co. | REITERATE | — | Buy |
| Mar 31, 2023 | HC Wainwright & Co. | REITERATE | — | Buy |
| Mar 1, 2023 | HC Wainwright & Co. | REITERATE | — | Buy |
| Feb 7, 2023 | Cantor Fitzgerald | MAINTAIN | — | Overweight |
| Jan 24, 2023 | Evercore ISI Group | MAINTAIN | — | Outperform |
| Dec 30, 2022 | Evercore ISI Group | MAINTAIN | — | Outperform |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 3 | 9 | 2 | 1 | 0 | 80% | |
| May 1, 2026 | 3 | 9 | 2 | 1 | 0 | 80% | |
| Apr 1, 2026 | 3 | 9 | 2 | 1 | 0 | 80% | |
| Mar 1, 2026 | 3 | 9 | 2 | 1 | 0 | 80% | |
| Feb 1, 2026 | 3 | 9 | 2 | 1 | 0 | 80% | |
| Jan 1, 2026 | 3 | 9 | 2 | 1 | 0 | 80% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 3, 2026
fda
TG Therapeutics Announces Positive Results from Phase 1 Trial Evaluating Subcutaneous BRIUMVI® (ublituximab-xiiy)
<p><em>Pharmacokinetic and pharmacodynamic data support quarterly subcutaneous BRIUMVI dosing regimen currently under evaluation in fully enrolled Pha
Jun 2, 2026
other
TG Therapeutics to Participate in the Goldman Sachs 47th Annual Healthcare Conference
Fireside chat scheduled for Tuesday, June 9, 2026, at 2:00 PM ET <pre>Fireside chat scheduled for Tuesday, June 9, 2026, at 2:00 PM ET</pre>
Jun 1, 2026
fda
TG Therapeutics Announces Publication of Post-Hoc Data from the Phase 3 ULTIMATE I & II Trials in Treatment Naive Patients with Relapsing Forms of MS Published in Frontiers in Immunology
<p><em>Treatment with BRIUMVI reduced annualized relapse rate by 56.7% vs. teriflunomide in treatment-naïve patients </em></p>
May 28, 2026
other
TG Therapeutics to Participate in the Jefferies Global Healthcare Conference
Fireside chat scheduled for Wednesday, June 3, 2026, at 11:40 AM ET <pre>Fireside chat scheduled for Wednesday, June 3, 2026, at 11:40 AM ET</pre>
May 27, 2026
other
TG Therapeutics Announces Positive Topline Results from Phase 3 ENHANCE Trial
<p><em>Phase 3 trial met its primary endpoint, demonstrating bioequivalent drug exposure between the currently approved BRIUMVI Day 1 and Day 15 initi
May 26, 2026
routine
TG Therapeutics Announces Data Presentations for BRIUMVI® at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting
<p>NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlight
May 14, 2026
short_interest
FTD: TGTX — 39,537 shares ($1.7M) failed to deliver
Settlement: 20260514, Price: $42.65, FTD Value: $1,686,253.05, TG THERAPEUTICS, INC. COMMON S
May 11, 2026
earnings_calendar
TGTX Q1 2026 Earnings Scheduled — 2026-05-11
May 11, 2026
short_interest
FTD: TGTX — 19,544 shares ($0.8M) failed to deliver
Settlement: 20260511, Price: $42.86, FTD Value: $837,655.84, TG THERAPEUTICS, INC. COMMON S
May 8, 2026
short_interest
FTD: TGTX — 116,034 shares ($5.0M) failed to deliver
Settlement: 20260508, Price: $43.03, FTD Value: $4,992,943.02, TG THERAPEUTICS, INC. COMMON S
May 6, 2026
earnings
TG Therapeutics Reports First Quarter 2026 Financial Results and Raises BRIUMVI Revenue Guidance
<p><em>First quarter 2026 total global revenue of approximately $205 million, including BRIUMVI U.S. net revenue of approximately $195 million</em></p
May 6, 2026
earnings_calendar
TGTX Q1 2026 Earnings Scheduled — 2026-05-06
May 4, 2026
earnings_calendar
TGTX Q1 2026 Earnings Scheduled — 2026-05-04
Apr 30, 2026
earnings
TG Therapeutics to Host Conference Call on First Quarter 2026 Financial Results and Business Update
Conference Call to be Held Wednesday, May 6, 2026, at 8:30 am ET <pre>Conference Call to be Held Wednesday, May 6, 2026, at 8:30 am ET</pre>
Apr 30, 2026
short_interest
FTD: TGTX — 29,276 shares ($1.0M) failed to deliver
Settlement: 20260430, Price: $33.58, FTD Value: $983,088.08, TG THERAPEUTICS, INC. COMMON S